NCT03311919

Brief Summary

The aim of this study is to describe the frequency of the presence of cells Natural Killer (NK) expressing CD86 and HLA - DR in tonsils

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2014

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2014

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2014

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

September 27, 2017

Completed
20 days until next milestone

First Posted

Study publicly available on registry

October 17, 2017

Completed
Last Updated

October 17, 2017

Status Verified

September 1, 2017

Enrollment Period

4 months

First QC Date

September 27, 2017

Last Update Submit

October 16, 2017

Conditions

Tonsillectomy

Outcome Measures

Primary Outcomes (1)

  • presence of lymphocytes NK expressing CD86 and HLA - DR

    by immunostaining and detection by flow cytometry

    inclusion

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patient with tonsillectomy

You may qualify if:

  • patient with programmed tonsillectomy as part of the care

You may not qualify if:

  • patient opposition to use its waste of per-operating tonsillectomy for research purposes
  • patient with immunosuppressive and/or corticoid treatment (\> 1 mg/kg)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, Wijdenes J, Adotevi O, Ferrand C, Romero P, Godet Y, Borg C. IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner. J Immunol. 2016 Jul 1;197(1):85-96. doi: 10.4049/jimmunol.1501147. Epub 2016 May 27.

    PMID: 27233967BACKGROUND

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 27, 2017

First Posted

October 17, 2017

Study Start

January 1, 2014

Primary Completion

May 1, 2014

Study Completion

December 31, 2014

Last Updated

October 17, 2017

Record last verified: 2017-09